To Register, go to: http://www.epliveonline.org/cyberonics20080608.html
Treatment Options for the Developmentally Delayed Patient with Epilepsy
When: June 08, 2008 / 7:30 9:00 PM EDT
Live
This seminar will take place at the Developmental Disabilities Nurses Association (DDNA) Annual Education Conference to be held in Foxwoods Resorts, CT this June.
Online
Join EP LiveOnline to view the event live on the internet‹free of charge and nation-wide. The archived (streaming video) version of the event will then be posted for 90 days following the live event on: http://www.epliveonline.org/eplive-archive3.html
Who Should Attend
Parents, families, caregivers, teachers, school nurses, developmental disability nurses, police, firemen, first-responders, coaches, primary care practitioners, pediatricians and all who work with children and adults who have epilepsy and seizure disorders, Exceptional Family Member Program of the U.S. Military
This program is made possible by an educational grant from Cyberonics, Inc.
There is no registration fee to participate in this program.
Presented by
Lucretia Long, RN, MS CNP
Assistant Clinical Professor, Neurology, Ohio State University, College of Medicine, Columbus, Ohio
Supported by
The American Academy of Development Medicine and Dentistry, Epilepsy Foundation of New Jersey.
To Register, go to: http://www.epliveonline.org/cyberonics20080608.html
Showing posts with label seizure medication. Show all posts
Showing posts with label seizure medication. Show all posts
Friday, May 9, 2008
Saturday, May 3, 2008
Epilepsy Drug Dilantin May Speed Bone Loss
Researchers report that young women taking the epilepsy drug Dilantin may risk bone loss and fracture with long-term use.
In a recent study, researchers followed 93 premenopausal women (age 18-40) taking one of four different epilepsy drugs: carbamazepine (also known with brand names Tegretol and Carbatrol), lamotrigine (Lamictal), valproate (Depakene), and Dilantin, for one year. Bone mineral density of the spine and two areas of the hip (femoral neck and total hip) were measured at the start and end of the study.
The results, published in Neurology, showed that women taking Dilantin experienced an average of 2.6% bone loss in the femoral neck only. No significant bone loss was found among those taking the other three epilepsy drugs.
Click here to learn more
In a recent study, researchers followed 93 premenopausal women (age 18-40) taking one of four different epilepsy drugs: carbamazepine (also known with brand names Tegretol and Carbatrol), lamotrigine (Lamictal), valproate (Depakene), and Dilantin, for one year. Bone mineral density of the spine and two areas of the hip (femoral neck and total hip) were measured at the start and end of the study.
The results, published in Neurology, showed that women taking Dilantin experienced an average of 2.6% bone loss in the femoral neck only. No significant bone loss was found among those taking the other three epilepsy drugs.
Click here to learn more
Subscribe to:
Posts (Atom)
